Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
200 employees
Rénibus Therapeutics: A biotech leader in preventing, treating, and diagnosing kidney disease.
HQ
Founded
2016
Rénibus Therapeutics is a biotech company dedicated to transforming the cardio-renal disease treatment paradigm by focusing on the prevention, treatment, and diagnostic testing of kidney disease. Their mission is to improve patient outcomes through innovative therapies and diagnostics, targeting a market with significant unmet medical needs.
Rénibus Therapeutics has made significant strides in the biotech industry, developing groundbreaking treatments and diagnostic tools for kidney disease. Their impactful work has garnered attention from leading healthcare professionals and investors, positioning them as a key player in the field of cardio-renal health.
Operating Status
Active
Ownership Type(s)
Venture Capital, Equity
Main Product(s)
Biotech
Tags
SaaS
Model Types
Recurring
Revenue Type(s)
Healthcare
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Renibus Therapeutics founded?
Renibus Therapeutics was founded in 2016.
Where is Renibus Therapeutics's headquarters located?
Renibus Therapeutics's headquarters is located in Southlake, US.
When was Renibus Therapeutics's last funding round?
Renibus Therapeutics's most recent funding round was for $25M (USD) in September 2023.
How many employees does Renibus Therapeutics have?
Renibus Therapeutics has 200 employees as of Feb 5, 2024.
How much has Renibus Therapeutics raised to-date?
As of July 05, 2023, Renibus Therapeutics has raised a total of $214.7M (USD) since Sep 12, 2023.
Add Comparison
Total Raised to Date
$214.7M
USD
Last Update Sep 12, 2023
Last Deal Details
$25M
USD
Sep 12, 2023
Series B
Current Employees
200
Last updated: Feb 5, 2024
No location information available for this company.
Locations
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts